Printer Friendly

GAMMA BIOLOGICALS REVIEWS ELECTRO-BIOSENSOR PROJECT; TESTS CONFIRM PROJECT FEASIBILITY; DEVELOPMENT TO CONTINUE

 HOUSTON, May 13 /PRNewswire/ -- Gamma Biologicals, Inc. (AMEX: GBL) reported today that the company's board of directors conducted a full review of the electro-biosensor project at its May 11, 1993 meeting. As previously reported, resources had been committed to fund development through April 1993, with a subsequent evaluation scheduled.
 The board determined that in-house test results obtained to date confirm the project feasibility and approved funding of continuing development efforts. Because the contributions of the outside engineering/design consultants, employed from April 1991 through February 1993, may not be utilized, the decision was made to expense previously capitalized device development charges of approximately $500,000 at March 31, 1993.
 In February 1991, Gamma acquired from the University of Texas M.D. Anderson Cancer Center the exclusive worldwide rights to a patent covering a new in-vitro diagnostic testing system utilizing electro- biosensor technology. This technique detects the first phase of bacterial, viral or blood group antigen/antibody reactions. Present diagnostic test results usually depend upon interpretation of agglutination (clumping), solid- phase adherence, fluorescence or color development, which may require up to 24 hours. The immunoelectrode technique detects change in electrical charge as a positive test result in less than five minutes. The advantages of this testing system are speed and accuracy, while obtaining objectivity, as the results are determined by electrical impulse.
 Gamma began in-house research into this diagnostic testing concept in 1989. In March 1993, Gamma filed its own patent application utilizing the Redox (reduction/oxidation) approach to biosensor testing.
 Future funding for the electro-biosensor project will be contingent upon continued progress being made toward development of a reliable test system. The company is not aware of any competitive efforts to utilize this new technology in the field of immunohematology.
 Gamma Biologicals manufactures and markets a wide range of highly refined and specialized testing products, known as diagnostic reagents, as well as sophisticated instrument systems. The company markets to hospitals, blood banks, medical laboratories, physicians' offices and research institutions. Gamma's common stock trades on the American Stock Exchange using the symbol GBL.
 -0- 5/13/93
 /CONTACT: John J. Moulds, president & COO, or Margaret J.O Bannion, Chief Financial Officer, both of Gamma Biologicals, Inc., 713-681-8481/
 (GBL)


CO: Gamma Biologicals, Inc. ST: Texas IN: MTC SU:

LR -- NY039 -- 8038 05/13/93 11:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 13, 1993
Words:385
Previous Article:MICHELE MARTIN NAMED ASSOCIATE PUBLISHER FOR SIMON & SCHUSTER TRADE DIVISION
Next Article:COGNITRONICS' SHAREHOLDERS TOLD OF FOCUS ON VOICE PROCESSING
Topics:


Related Articles
FINAL CASH SETTLEMENT ON ITALIAN SALE TO FUND BIOELECTRICAL SENSOR TECHNOLOGY DEVELOPMENT FOR GAMMA BIOLOGICALS
ANOTHER FIRST FOR GAMMA BIOLOGICALS; COMPANY RECEIVES FIRST EVER LICENSE FOR MONOCLONAL COOMBS REAGENTS
GAMMA BIOLOGICALS REPORTS STRONG EARNINGS FOR QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 1993
EDITEK, INC. ENTERS INTO RESEARCH PROGRAM WITH BATTELLE MEMORIAL INSTITUTE
GAMMA BIOLOGICALS REPORTS EARNINGS FOR SECOND QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 1995
GAMMA BIOLOGICALS REPORTS EARNINGS FOR THIRD QUARTER AND NINE MONTHS ENDED DEC. 31, 1995
GAMMA BIOLOGICALS RETAINS FINANCIAL ADVISER; VECTOR SECURITIES TO REVIEW STRATEGIC ALTERNATIVES
Gamma Biologicals Reports Earnings for the Third Quarter and Nine Months Ended December 31, 1996
GAMA BIOLOGICALS' SHARES DILUTED IN JOINT VENTURE
IGEN's Collaboration With U.S. Army on Toxins Is Being Fast Tracked.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters